Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
 - EconoTimes)
NEW YORK, March 11, 2016 -- Gainey McKenna & Egleston announces that the class action lawsuit they filed on behalf of their client was the first proposed class action lawsuit filed against Match Group, Inc. (“Match Group” or the “Company”) (Nasdaq:MTCH) and certain other defendants. It is pending in the United District Court for the Northern District of Texas on behalf of all persons or entities who purchased or otherwise acquired Match Group securities pursuant or traceable to the Company’s Registration Statement and Prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s Initial Public Offering (the “IPO”) which commenced on or about November 18, 2015. Plaintiff seeks to pursue remedies against Defendants under §§ 11, 12(a)(2) and 15 of the Securities Act of 1933.
On November 19, 2015, Match Group sold 33,333,333 shares at $12.00 per share as part of its Initial Public Offering. Then on February 2, 2016, Match Group revealed to investors a decline in total user growth and per-user revenue, and the cannibalization of users and revenues across competing platforms. They also revealed that the Company’s net income has consistently fallen and that there had been a decline in revenue in their Princeton Review segment.
Shares of Match Group fell from a close of $12.79 prior to the announcement, to a recent close of just $9.76 on February 4, 2016.
If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
